smc

Anagliptin (SK-0403) is a potent inhibitor of DPP-4 (IC50 of 3.8 nM) used in the treatment of type 2 diabetes mellitus.

SMCC (N-Succinimidyl 4-(N-maleimidomethyl)cycl) is a heterobifunctional protein crosslinker.

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.

Doxorubicin-SMCC is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.

DM4-SMCC, a non-cleavable drug-linker conjugate for antibody-drug conjugates (ADC), leverages the antitumor efficacy of DM4 (an antitubulin agent) through attachment with the SMCC linker, exhibiting antitumor activity[1].

MMAE-SMCC comprises the antitumour microtubule inhibitor MMAE and the non-cleavable ADC linker SMCC, enabling the preparation of antibody-drug conjugates (ADCs).

Sulfo-SMCC sodium, a widely utilized non-cleavable, hetero-bifunctional crosslinker for antibody-drug conjugates (ADCs), features both N-hydroxysuccinimide (NHS) ester and maleimide groups. These functionalities enable it to specifically react with primary amines and sulfhydryl groups, respectively.

trans-Sulfo-SMCC is a non-cleavable, membrane-permeable ADC crosslinker.

SmCB1-IN-1 (Compound 2h) is an inhibitor of the Schistosoma mansoni cathepsin B1 (SmCB1) with a Ki of 0.05 μM. It demonstrates selectivity towards non-target human proteases, showing inhibition rates of 29% for CatB and 37% for CatL at 20 μM. At 1 μM, SmCB1-IN-1 inhibits 68% of Schistosoma mansoni.

Paclitaxel-SMCC is a paclitaxel derivative with a SMCC linker. (Succinimidyl-4-( N -maleimidomethyl)cyclohexane-1-carboxylate). Paclitaxel-SMCC can be used to synthesize Paclitaxel bioconjugates with enzymes, antobodies, antigens and other biopolymers. Pa

Palbociclib-SMCC is a Palbociclib derivative with a SMCC linker.

SMCypIC31 is a non-peptide cyclophilin inhibitor that effectively inhibits peptidyl-prolyl cis/trans isomerase (PPIase) (IC50: 0.1 μM). SMCypI C31 has a pan-genotypic effect against HCV, with an EC50 range of 1.20-7.76 μM against genotypes 1a, 1b, 2a, 3a and 5a HCV-SGRs and chimeric genotypes 2a/4a HCV-SGRs.

Rha-PEG3-SMCC (Compound 13) serves as an ADC (antibody-drug conjugate) linkage agent with robust antitumor properties, utilizing the protein crosslinker SMCC, which is tethered through the non-cleavable linker Rha-PEG3.

(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemic form of Lys-SMCC-DM1, which serves as a linker-payload component capable of inhibiting tubulin polymerization. It is also recognized as the active metabolite of T-DM1 [1].

Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked with the SMCC linker and the cytotoxic microtubule inhibitor DM1. The ADC's toxic and linker components are SMCC-DM1. Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used for cancer research.

Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab linked to the cytotoxic microtubule inhibitor DM1 through the linker SMCC. The ADC's toxic molecule and linker component are SMCC-DM1. This compound is applicable in cancer research, particularly for studying prostate cancer.

Smcy HY Peptide (738-746) is an H2-Db-restricted peptide derived from amino acids 738 to 746 of the Smcy protein.

SMCY peptide blocks the interaction of an iodinated standard peptide with HLA-B7, exhibiting an IC50 of 34 nM. As an H-Y antigen epitope, it can be displayed by the HLA-B7 molecule and identified by specific T cells, potentially resulting in transplant rejection.

PSMA-1-SMCC is a selective ligand that targets the prostate-specific membrane antigen (PSMA). It holds potential for research applications in the targeted imaging of prostate cancer.

Hemocyanin-SMCC is a hemocyanin that functions as a carrier protein, facilitating the conjugation with peptides, nucleic acids, or small molecules to enhance their immunogenicity.

SMCC-NH-CH2-triazole-PEG8-oxydiacetamide-Lys(MTT)-PAB [Page 7, Compound C] is an ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Dimethyl sulfoxide (DMSO) is a commonly used solvent to dissolve polar and non-polar compounds. Dimethyl sulfoxide has been widely used for masterbatch preparation of compounds in biological experiments. Dimethyl sulfoxide has bacteriostatic activity.

N-Ethylmaleimide (NEM) is a reagent for alkylation of free sulfhydryl groups, a cysteine protease inhibitor used in experimental biochemistry. N-Ethylmaleimide is also a deubiquitinating enzyme inhibitor that specifically inhibits phosphate transport in mitochondria.